Gila Therapeutics is a Boston-based clinical stage biotech company exploiting a novel, highly-targeted neural signaling system for the treatment of obesity, type 2 diabetes and associated metabolic disorders. Our innovative Topical Lingual Neural Signaling platform facilitates the direct activation of specific brain regions responsible for metabolic regulation through the delivery of natural peptide hormones without expectation of side effects. Our scientific advisory team is renowned globally for their unrivaled experience and pioneering contributions to the fields of endocrinology, neuroscience, and metabolic nephrology. Reach out to learn more about us.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 198 Tremont St, Boston,ma 02216,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Boston, MA
Gila Therapeutics Questions
Gila Therapeutics's website is https://www.gilatherapeutics.com/
Gila Therapeutics's LinkedIn profile is https://www.linkedin.com/company/gila-therapeutics
Gila Therapeutics has
3 employees.
View email and phone details for 3
employees at Gila Therapeutics.
Gila Therapeutics's industry is
Biotechnology Research
Gila Therapeutics's top competitors are
Atavistik Bio,
Cinrx Pharma,
Preclinical Electrophysiology Consulting,
Ixcells Biotechnologies,
Ceretype Neuromedicine, Inc.,
Neurotechx,
Akili,
Lucy Therapeutics,
Vigil Neuroscience,
Phenomix Sciences.
Gila Therapeutics's categories are Biotechnology Research
Gila Therapeutics's founding year is 2014
